Evaluating the role of preoperative plasma insulin-like growth factor 1 (IGF-1) as a predictor of survival and recurrence in patients with resectable hepatocellular carcinoma.
Abstract
e16318 Background: Low serum Insulin-like Growth Factor 1 (IGF-1) levels are associated with multinodularity, and shorter overall survival (OS) in patients with advanced unresectable HCC. In this study, we sought to evaluate whether preoperative IGF-1 levels may also be associated with OS and recurrence-free survival (RFS) in patients who underwent hepatic resection for HCC. Methods: Patients undergoing hepatectomy for HCC from September 2001 to May 2023 were identified from a prospectively maintained database at a tertiary cancer referral center. Patients without levels of IGF-1 within 2 months of hepatectomy were excluded. The median level of IGF-1 was 87 and was used as a cutoff to categorize high vs low IGF-1 levels. This cutoff was used instead of the more established 50 as patients in surgical cohorts naturally have healthier livers, and thus higher levels of IGF-1 than advanced unresectable HCC on which this cutoff was established. The primary endpoint was OS and the secondary endpoint was RFS. The Kaplan-Meier method was used to compute the median OS and RFS, while multivariable Cox regression model was applied to study the association of serum IGF-1 levels with OS and RFS. Results: Fifty-one patients were included in this study. Median age was 66 years, with 33 males and 18 females. The median (IQR) IGF-1 value was 87 (57-124) ng/mL. Patients with low IGF-1 were more likely to be elderly (≥65), with a history of diabetes, hypertension, and tobacco use (p < 0.05 for all). They were also more likely to have multinodular tumors (31% vs 4%, p = 0.012), higher AFP levels (median 71 vs 3 ng/mL, p = 0.019), and BCLC stage B (31% vs 8%, p = 0.041). The median follow-up was 61 months. RFS was not significantly different between the high and low IGF-1 groups (1-year RFS 59% vs 64%, p = 0.545). OS was significantly longer in patients with high IGF-1 compared to patients with low IGF-1 (5-year OS 80% vs 40%, p = 0.027). On multivariable analysis, high IGF-1 was significantly associated with better OS (HR 0.33, 95% CI 0.12-0.93; p = 0.035). Conclusions: Low preoperative levels of IGF-1 was not associated with recurrence but it was a predictor of poor survival after liver resection for HCC. Since low plasma IGF-1 levels is associated with low hepatic reserve and increasing severity of chronic liver disease, our results may be explained by a decreased overall life expectancy and a decreased ability to intervene and provide alternative treatment options at time of recurrence in patients with low IGF (≤87 ng/mL).
Article Details
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
Authors (13)
Joe Eid
Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Antony Haddad
Department of Surgery, The University of Louisville, Louisville, KY
Sunyoung S. Lee
Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Zishuo Ian Hu
The University of Texas MD Anderson Cancer Center, Houston, TX
Manal Hassan
Hesham M. Amin
The University of Texas MD Anderson Cancer Center, Houston, TX
Timothy E. Newhook
The University of Texas MD Anderson Cancer Center, Houston, TX
Ching-Wei D. Tzeng
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Jean-Nicolas Vauthey
The University of Texas MD Anderson Cancer Center, Houston, TX
Yun Shin Chun
Emad D. Singer
University of Texas MD Anderson Cancer Center, Houston, TX
Hop Sanderson Tran Cao
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Ahmed Omar Kaseb
Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX